Skip to main content

Genetic Medicines’ Path to Scalability for Patients and Investors

Monday, February 26, 2024
Majestic Complex
More than 30 genetic medicine treatments have been approved by the FDA so far, with hundreds more in the clinical pipeline, but companies working in these newer modalities have been challenged by scaling up manufacturing and establishing reliable reimbursement paths. This panel will examine the risks and opportunities when commercializing genetic medicines and how best to fulfill the expectations of investors to support bringing these pioneering benefits to patients.
Geulah Livshits, Senior Research Analyst - Chardan Capital Markets
Alexandra Forbes, President and Chief Executive Officer - MeiraGTx
Joe Nolan, Chief Executive Officer - Jaguar Gene Therapy
Nolan Townsend, CEO and Director - Lexeo Therapeutics

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.